Alopecia Areata clinical trial for adolescent age 6-18, evaluating the safety and efficacy of Baricitinib.
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE-AA-PEDS)
More information about the study available here: https://www.clinicaltrials.gov/study/NCT05723198?term=I4V-MC-JAIO&rank=1
Sites running the trial are:
Skin and Cancer Foundation Australia – Darlinghurst Clinic
Contact: 8651 2027 Principal Investigator: Johanna Kuchel
Royal North Shore Hospital St Leonards,
Principal Investigator: Rebecca Saunderson
Veracity Clinical Research, Woolloongabba, QLD
Principal Investigator: Lynda Spelman
Sinclair Dermatology ,Melbourne, Victoria, Australia, 3002
Principal Investigator: Samantha Eisman
Institute for Skin, Health, and Immunity Mitcham, Victoria, Australia, 3132